出血性疾患治療の世界市場レポート 2025年

出血性疾患治療の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.0％で261億4,000万米ドルに成長します。予測期間の成長は、高齢化、個別化医療、患者擁護と支援、可処分所得の増加、ヘルスケア支出の増加に起因しています。予測期間の主な動向には、個別化治療計画、遠隔医療サービスの拡大、先進凝固因子治療、RNAベース治療、希少疾病用医薬品指定へのアクセスなどが含まれます。

出血性疾患治療市場の成長は、血友病と診断される患者数の増加によって促進されると予測されます。血友病は、血液凝固不全を特徴とする遺伝性出血性疾患であり、治療には補充療法が必要です。これには、欠損した血液凝固因子をヒト血漿濃縮製剤または組換え型血液凝固因子VIIIまたはIXで置換することが含まれます。2021年、世界血友病連盟は、世界中で約23万4千人の血友病患者が確認されたと報告しました。診断された血友病患者数の増加は、出血性疾患治療市場の成長を支える重要な要因であり、この遺伝性疾患に対する治療法の進歩の重要性を強調しています。

ヘルスケア支出の増加は、今後数年間の出血性疾患治療市場の成長を促進すると予想されます。ヘルスケア支出とは、医療費に対する総支出のことで、特定の医療制度や経済圏内で医療関連の商品やサービスに割り当てられるすべての資金を含みます。この支出は、出血性疾患の治療法の開発と利用しやすさを支えるために不可欠です。例えば、2024年10月、米国の連邦機関であるメディケアメディケイドサービスセンターは、GDPに占める医療費の割合が2022年の17.3％から2032年には19.7％に上昇したと報告しました。このように、医療支出の増加が出血性疾患治療市場の拡大を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の出血性疾患治療市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の出血性疾患治療市場の成長率分析
• 世界の出血性疾患治療市場の実績：規模と成長、2019～2024年
• 世界の出血性疾患治療市場の予測：規模と成長、2024～2029年、2034年
• 世界の出血性疾患治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の出血性疾患治療市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• デスモプレシン（DDAVP）
• ホルモン補充療法
• 避妊薬
• 抗線溶薬または血栓安定化薬
• フィブリンシーラント
• 切り傷治療薬
• パイプライン分析
• 世界の出血性疾患治療市場：疾患タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 血友病A
• 血友病B
• フォンヴィレブランド病
• 肝臓病
• その他の疾患
• 世界の出血性疾患治療市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 専門クリニック
• 研究機関
• その他のエンドユーザー
• 世界の出血性疾患治療市場：デスモプレシン（DDAVP）のサブセグメンテーション：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 静脈内製剤
• 鼻スプレー製剤
• 世界の出血性疾患治療市場：ホルモン補充療法のサブセグメンテーション：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• エストロゲン療法
• プロゲステロン療法
• 世界の出血性疾患治療市場：避妊薬のサブセグメンテーション：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 複合経口避妊薬
• プロゲスチン単独避妊薬
• 世界の出血性疾患治療市場：抗線溶薬または血栓安定化薬のサブセグメンテーション：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• トラネキサム酸
• アミノカプロン酸
• 世界の出血性疾患治療市場：フィブリンシーラントのサブセグメンテーション：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• ティセール
• アーティス
• 世界の出血性疾患治療市場：切り傷治療薬のサブセグメンテーション：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 防腐剤
• 局所止血剤
• 世界の出血性疾患治療市場：パイプライン分析のサブセグメンテーション：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 開発中の今後の治療法
• 新しい治療法と技術

第7章 地域別・国別分析

• 世界の出血性疾患治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の出血性疾患治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 出血性疾患治療市場：競合情勢
• 出血性疾患治療市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• CSL Behring Company
• Grifols SA
• Octapharma AG
• BDI Pharma Inc.
• Ferring Pharmaceuticals Ltd.
• Xenetic Biosciences Inc.
• Sanofi SA
• Alnylam Pharmaceuticals Inc.
• Novartis AG
• Shire plc
• Novo Nordisk
• Grifols SA
• F. Hoffmann-La Roche AG
• Sanofi Corporation
• Takeda Pharmaceutical Company Limited

第32章 世界市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 市場の最近の動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 出血性疾患治療市場2029年-最も新しい機会を提供する国
• 出血性疾患治療市場2029年-最も新しい機会を提供するセグメント
• 出血性疾患治療市場2029年-成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Bleeding disorders constitute a category of medical conditions characterized by inadequate blood clotting, leading to prolonged bleeding following surgery, injury, menstruation, or trauma. The management of these disorders aims to either arrest or diminish the frequency of bleeding episodes.

Key modalities in the treatment of bleeding disorders encompass desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic or clot-stabilizing medications, fibrin sealants, drugs for topical application on cuts, and pipeline analysis. Desmopressin (DDAVP) therapies play a pivotal role in diagnosing individuals with mild hemophilia A or von Willebrand disease, effectively halting bleeding. Targeted diseases include hemophilia A, hemophilia B, von Willebrand disease, liver disease, and others. These interventions cater to diverse end users, including hospitals, clinics, specialty clinics, research institutes, and related entities.

The bleeding disorders treatment market research report is one of a series of new reports from The Business Research Company that provides Bleeding disorders treatment market statistics, including bleeding disorders treatment industry global market size, regional shares, competitors with bleeding disorders treatment market share, detailed Bleeding disorders treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the bleeding disorders treatment industry. This bleeding disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bleeding disorders treatment market size has grown strongly in recent years. It will grow from $16.95 billion in 2024 to $18.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to increased patient awareness, access to healthcare, advancements in hemophilia therapies, global market expansion.

The bleeding disorders treatment market size is expected to see strong growth in the next few years. It will grow to $26.14 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to aging population, personalized medicine, patient advocacy and support, rise in disposable income, rise in healthcare expenditure. Major trends in the forecast period include personalized treatment plans, expansion of telehealth services, advanced clotting factor therapies, rna-based treatments, access to orphan drug designation.

The growth of the bleeding disorders treatment market is anticipated to be propelled by the increasing number of diagnosed hemophilia patients. Hemophilia, an inherited bleeding disorder characterized by inadequate blood clotting, necessitates replacement therapy for treatment. This involves replacing the deficient blood clotting factors with human plasma concentrates or recombinant forms of clotting factors VIII or IX. In 2021, the World Federation of Hemophilia reported nearly 234,000 confirmed cases of hemophilia worldwide. The escalating number of diagnosed hemophilia patients is a significant driver behind the growth of the bleeding disorders treatment market, emphasizing the importance of advancing treatments for this inherited disorder.

The increasing healthcare expenditure is expected to fuel the growth of the bleeding disorders treatment market in the coming years. Healthcare expenditure refers to the total spending on healthcare costs, encompassing all money allocated to healthcare-related goods and services within a specific healthcare system or economy. This expenditure is vital for supporting the development and accessibility of treatments for bleeding disorders. For example, in October 2024, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported that the health spending share of GDP rose from 17.3 percent in 2022 to 19.7 percent in 2032. Thus, the rise in healthcare expenditure is driving the expansion of the bleeding disorders treatment market.

Major companies in the bleeding disorder treatment market are concentrating on the development of innovative technologies, such as single-dose treatments, to improve treatment efficacy and enhance patient quality of life by reducing the necessity for ongoing therapies. Single-dose treatment refers to a therapeutic strategy that provides a complete treatment with a single administration, aiming for long-lasting effects without the requirement for multiple doses. For example, in June 2023, BioMarin Pharmaceutical Inc., a US-based biotechnology firm, introduced BioMarin's ROCTAVIANTM (valoctocogene roxaparvovec-rvox). ROCTAVIAN is specifically designed for adults with severe hemophilia A (characterized by FVIII activity levels below 1 IU/dL) who do not have pre-existing antibodies to adeno-associated virus serotype 5 (AAV5) as confirmed by an FDA-approved test.

Leading companies in the bleeding disorder treatment market are actively developing on-demand treatments to control bleeding episodes and perioperative management solutions, addressing a broader customer base and aiming to boost sales and revenue. On-demand treatment is a crucial aspect of managing bleeding disorders, empowering individuals to respond promptly to bleeding episodes and ensuring safe perioperative care during surgical procedures. Ongoing advances in clotting factor therapies and treatment strategies are enhancing the overall quality of life for individuals with bleeding disorders, enabling them to lead more active and fulfilling lives. In February 2023, the collaboration between Sanofi and Sobi resulted in the development of the first-in-class, high-sustained factor VIII replacement therapy known as ALTUVIIIO, which received U.S. FDA approval. This groundbreaking medication offers a unique once-a-week dosing schedule, producing factor activity levels above 40% for the majority of the week and significantly reducing bleeding compared to previous factor VIII prophylaxis.

In October 2022, Pfizer Inc., a prominent U.S.-based pharmaceutical and biotechnology corporation, made a strategic move by acquiring Global Blood Therapeutics, Inc. (GBT) for an undisclosed amount. This acquisition was geared towards leveraging GBT's portfolio to expedite discovery processes and provide a range of potential best-in-class medicines for patients with sickle cell disease. Global Blood Therapeutics, Inc., a U.S.-based biopharmaceutical company specializing in the treatment of blood disorders, contributed valuable expertise and products to Pfizer's portfolio, aligning with the broader industry trend of strategic acquisitions to strengthen capabilities and enhance the range of therapeutic offerings in the bleeding disorder treatment market.

Major companies operating in the bleeding disorders treatment market include AbbVie Inc., Bayer AG, Novo Nordisk A/S, Pfizer Inc., Biogen Inc., CSL Behring Company, Grifols SA, Octapharma AG, BDI Pharma Inc., Ferring Pharmaceuticals Ltd., Xenetic Biosciences Inc., Sanofi SA, Alnylam Pharmaceuticals Inc., Novartis AG, Shire plc, Novo Nordisk, Grifols SA, F. Hoffmann-La Roche AG, Sanofi Corporation, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, Biotest AG, LFB S.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., HEMA Biologics LLC, ADMA Biologics Inc., Grifols Biologicals Inc., Octapharma Plasma Inc., Kedrion Biopharma Inc., BPL Plasma Inc., BioLife Plasma Services, CSL Plasma Ltd., Grifols Shared Services North America Inc., Octapharma USA Inc., Shire US Inc., Pfizer Canada Inc., Grifols Canada Ltd., Octapharma Canada Inc.

North America was the largest region in the bleeding disorders treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bleeding disorders treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the bleeding disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The bleeding disorders treatment market includes revenues earned by entities by recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bleeding Disorders Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bleeding disorders treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bleeding disorders treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bleeding disorders treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Desmopressin (DDAVP); Hormone Replacement Therapy; Contraceptives; Anti-Fibrinolytic or Clot-Stabilizing Drugs; Fibrin Sealants; Drugs Applied To Cuts; Pipeline Analysis
• 2) By Disease Type: Hemophilia A; Hemophilia B; Von Willebrand disease; Liver disease; Other Disease Types
• 3) By End User: Hospitals; Clinics; Specialty Clinics; Research Institutes; Other End Users
• Subsegments:
• 1) By Desmopressin (DDAVP): Intravenous Formulations; Nasal Spray Formulations
• 2) By Hormone Replacement Therapy: Estrogen Therapy; Progesterone Therapy
• 3) By Contraceptives: Combined Oral Contraceptives; Progestin-Only Contraceptives
• 4) By Anti-Fibrinolytic or Clot-Stabilizing Drugs: Tranexamic Acid; Aminocaproic Acid
• 5) By Fibrin Sealants: Tisseel; Artiss
• 6) By Drugs Applied To Cuts: Antiseptics; Topical Hemostatic Agents
• 7) By Pipeline Analysis: Upcoming Treatments in Development; Novel Therapeutics and Technologies
• Companies Mentioned: AbbVie Inc.; Bayer AG; Novo Nordisk A/S; Pfizer Inc.; Biogen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Bleeding Disorders Treatment Market Characteristics

3. Bleeding Disorders Treatment Market Trends And Strategies

4. Bleeding Disorders Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Bleeding Disorders Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Bleeding Disorders Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Bleeding Disorders Treatment Market Growth Rate Analysis
• 5.4. Global Bleeding Disorders Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Bleeding Disorders Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Bleeding Disorders Treatment Total Addressable Market (TAM)

6. Bleeding Disorders Treatment Market Segmentation

• 6.1. Global Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Desmopressin (DDAVP)
• Hormone Replacement Therapy
• Contraceptives
• Anti-Fibrinolytic or Clot-Stabilizing Drugs
• Fibrin Sealants
• Drugs Applied to Cuts
• Pipeline Analysis
• 6.2. Global Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Liver Disease
• Other Disease Types
• 6.3. Global Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Specialty Clinics
• Research Institutes
• Other End Users
• 6.4. Global Bleeding Disorders Treatment Market, Sub-Segmentation Of Desmopressin (DDAVP), By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Formulations
• Nasal Spray Formulations
• 6.5. Global Bleeding Disorders Treatment Market, Sub-Segmentation Of Hormone Replacement Therapy, By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Estrogen Therapy
• Progesterone Therapy
• 6.6. Global Bleeding Disorders Treatment Market, Sub-Segmentation Of Contraceptives, By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combined Oral Contraceptives
• Progestin-Only Contraceptives
• 6.7. Global Bleeding Disorders Treatment Market, Sub-Segmentation Of Anti-Fibrinolytic or Clot-Stabilizing Drugs, By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tranexamic Acid
• Aminocaproic Acid
• 6.8. Global Bleeding Disorders Treatment Market, Sub-Segmentation Of Fibrin Sealants, By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tisseel
• Artiss
• 6.9. Global Bleeding Disorders Treatment Market, Sub-Segmentation Of Drugs Applied To Cuts, By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiseptics
• Topical Hemostatic Agents
• 6.10. Global Bleeding Disorders Treatment Market, Sub-Segmentation Of Pipeline Analysis, By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Upcoming Treatments in Development
• Novel Therapeutics and Technologies

7. Bleeding Disorders Treatment Market Regional And Country Analysis

• 7.1. Global Bleeding Disorders Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Bleeding Disorders Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Bleeding Disorders Treatment Market

• 8.1. Asia-Pacific Bleeding Disorders Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Bleeding Disorders Treatment Market

• 9.1. China Bleeding Disorders Treatment Market Overview
• 9.2. China Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Bleeding Disorders Treatment Market

• 10.1. India Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Bleeding Disorders Treatment Market

• 11.1. Japan Bleeding Disorders Treatment Market Overview
• 11.2. Japan Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Bleeding Disorders Treatment Market

• 12.1. Australia Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Bleeding Disorders Treatment Market

• 13.1. Indonesia Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Bleeding Disorders Treatment Market

• 14.1. South Korea Bleeding Disorders Treatment Market Overview
• 14.2. South Korea Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Bleeding Disorders Treatment Market

• 15.1. Western Europe Bleeding Disorders Treatment Market Overview
• 15.2. Western Europe Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Bleeding Disorders Treatment Market

• 16.1. UK Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Bleeding Disorders Treatment Market

• 17.1. Germany Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Bleeding Disorders Treatment Market

• 18.1. France Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Bleeding Disorders Treatment Market

• 19.1. Italy Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Bleeding Disorders Treatment Market

• 20.1. Spain Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Bleeding Disorders Treatment Market

• 21.1. Eastern Europe Bleeding Disorders Treatment Market Overview
• 21.2. Eastern Europe Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Bleeding Disorders Treatment Market

• 22.1. Russia Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Bleeding Disorders Treatment Market

• 23.1. North America Bleeding Disorders Treatment Market Overview
• 23.2. North America Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Bleeding Disorders Treatment Market

• 24.1. USA Bleeding Disorders Treatment Market Overview
• 24.2. USA Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Bleeding Disorders Treatment Market

• 25.1. Canada Bleeding Disorders Treatment Market Overview
• 25.2. Canada Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Bleeding Disorders Treatment Market

• 26.1. South America Bleeding Disorders Treatment Market Overview
• 26.2. South America Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Bleeding Disorders Treatment Market

• 27.1. Brazil Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Bleeding Disorders Treatment Market

• 28.1. Middle East Bleeding Disorders Treatment Market Overview
• 28.2. Middle East Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Bleeding Disorders Treatment Market

• 29.1. Africa Bleeding Disorders Treatment Market Overview
• 29.2. Africa Bleeding Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Bleeding Disorders Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Bleeding Disorders Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Bleeding Disorders Treatment Market Competitive Landscape And Company Profiles

• 30.1. Bleeding Disorders Treatment Market Competitive Landscape
• 30.2. Bleeding Disorders Treatment Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Bleeding Disorders Treatment Market Other Major And Innovative Companies

• 31.1. CSL Behring Company
• 31.2. Grifols SA
• 31.3. Octapharma AG
• 31.4. BDI Pharma Inc.
• 31.5. Ferring Pharmaceuticals Ltd.
• 31.6. Xenetic Biosciences Inc.
• 31.7. Sanofi SA
• 31.8. Alnylam Pharmaceuticals Inc.
• 31.9. Novartis AG
• 31.10. Shire plc
• 31.11. Novo Nordisk
• 31.12. Grifols SA
• 31.13. F. Hoffmann-La Roche AG
• 31.14. Sanofi Corporation
• 31.15. Takeda Pharmaceutical Company Limited

32. Global Bleeding Disorders Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bleeding Disorders Treatment Market

34. Recent Developments In The Bleeding Disorders Treatment Market

35. Bleeding Disorders Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Bleeding Disorders Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Bleeding Disorders Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Bleeding Disorders Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer